SEC Form 4 · accession 0001602474-26-000004
Whitehawk Therapeutics, Inc. · WHWK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anupam Dalal
Director
Period of report
May 14, 2026
Accepted (ET)
Jul 30, 2026 · 4:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001422142
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 14, 2026 | A | 1,275,510 | $3.92 | A | 4,685,912 | I | See footnote |
| Common Stock | holding | — | — | — | 1,130 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $4.16 | Jun 12, 2026 | A | 38,040 | A | — | Jun 12, 2036 | Common Stock | 38,040 | 38,040 | D |
Explanation of responses
- F1Consists of (i) 3,538,288 shares held by Acuta Capital Fund, LP ("Acuta Capital") and (ii) 1,147,624 shares held by Acuta Opportunity Fund, LP. ("Acuta Opportunity Fund"). Acuta Capital Partners, LLC ("Acuta Partners") is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Managing Member of Acuta Partners. The Reporting Person has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and the Reporting Person disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein.
- F2Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.